The first CRISPR and Translational Medicine Congress was held on March 31 and April 1st, 2022 in Bordeaux.
CRISPR is one of the most powerful discoveries of the last decade and the scientific program of the congress is organized in six sessions dealing with major aspects of current developments:
The CRISPR-Cas9 technology has revolutionized genome edition approaches in the last few years. It is used to model genetic diseases in both in vitro cell lines or primary cells (sessions 1 and 2) and in vivo animal models (session 3). First therapeutic trials in humans have been undertaken (session 4), further strengthening the clinical prospects of the technology. Meanwhile, the intensive use of CRISPR tool in research labs has revealed off-target effects with unwanted genetic modifications (session 5), and many current researches are focused on the improvement of DNA targeting and cutting action of CRISPR tools in order to overcome these drawbacks and develop new applications (session 6).
A round table presenting the CRISPR technology and the societal and ethical aspects was organized on Friday evening.
LThe round table is moderated by Cyril Sarrauste de Menthière, ingénieur de recherche CNRS de l’Institut de génétique humaine (IGH, CNRS et université de Montpellier), head of the Scientific Mediation and Valorization Service.
Organizing Committee, a large part of which is a member of BRIC: